title: A comparative study on long-term MTX controlled release from intercalated nanocomposites for nanomedicine applications.
abstract: The feasibility of some mesoporous materials such as SBA-15 and MCM-41 silica, LDH (layered double hydroxide) (Mg3Al-NO3) and MC (mesoporous carbon) have been comparatively evaluated for oral drug delivery applications, in order to broaden the range of matrices and implicitly to develop the class of drug delivery systems based on diffusion mechanism. As well known, methotrexate (MTX) is used widely to treat various neoplastic diseases such as acute lymphoblast leukemia, lymphoma and solid cancers and autoimmune diseases such as psoriasis and rheumatoid arthritis. The commercially available formulations of this drug have disadvantages due to the traditional release process that occurs in the body. Thus, this work is focused on the long-term controlled MTX delivery because this one could eliminate over or underdosing, could maintain drug levels in desired range, could increase patient compliance and prevent the side effects. Therefore, the mesoporous materials are used and efficient MTX-delivery systems, based on above-mentioned mesoporous materials, are successfully prepared by intercalation. The obtained drug carriers were tested in the controlled MTX-drug release process and the influence of the pore morphology and geometry on MTX release profiles was extensively studied comparatively. The prepared MTX delivery systems were characterized by FTIR and UV-vis spectroscopy, N2 sorption measurements. Then, the data obtained from the in vitro release studies have been analyzed, and in order to evaluate the MTX-release mechanism and kinetics, the Korsmeyer-Peppas equation has been applied.
authors: Alexandru Ioan Cuza University, Faculty of Chemistry, Iasi, Romania.
authors: Iuliana Florentina
authors: IF
authors: Alexa
authors: Cristina Giorgiana
authors: CG
authors: Pastravanu
authors: Maria
authors: M
authors: Ignat
authors: Evelini
authors: E
authors: Popovici
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D003692:Delayed-Action Preparations; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage*; D053761:Nanocomposites; D050997:Nanomedicine; D010349:Patient Compliance; D013056:Spectrophotometry, Ultraviolet; D017550:Spectroscopy, Fourier Transform Infrared; D013816:Thermodynamics
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D007166:Immunosuppressive Agents; D008727:Methotrexate